A Phase I/II clinical trial of vemurafenib in dogs with BRAF mutant UC determined that the observed safety, anti-tumour activity, and cutaneous pharmacodynamic effects of vemurafenib (specifically the development of cutaneous squamous cell carcinoma and papillomas) closely mimicked those reported in humans [59]. Here, BRAF is linked to neoplasm.